Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry

Back

ESC Professional Premium Access

Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry

Session: Remodelling, prognosis, and outcomes in atrial fibrillation

Topic: Antiarrhythmic Drug Treatment

Speaker: Doctor D. Morrone (Pisa, IT)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Doralisa Morrone

Cisanello Hospital, Pisa (Italy)

2 presentations

0 follower

7 more presentations in this session

Duration of left and right atrial activation wavefront assessed non-invasively is significantly higher in patients with atrial fibrillation than in controls.

Speaker: Doctor L. Parreira (Setubal, PT)

The risk and cause of death according to prevalent atrial fibrillation and the role of CHA2DS2-VASc score to stratify the risk of all-cause and cardiovascular death

Speaker: Doctor Y. Kim (Seoul, KR)

Lower risk of atrial fibrillation development associated with SGLT-2 inhibitors in type 2 diabetic patients compared to DPP-4 inhibitors: a nationwide cohort study

Speaker: Doctor J. Lee (Cheongju, KR)

Access

Abstract

Slides

Impact of atrial fibrillation burden on longitudinal changes in left ventricular structure and function: a post-hoc analysis of a randomized clinical trial

Speaker: Miss F. Vyff (Gentofte, DK)

Prognostic significance of thyroid disease in atrial fibrillation

Speaker: Doctor A. Papazoglou (Athens, GR)

Access the full session

Remodelling, prognosis, and outcomes in atrial fibrillation

Speakers: Doctor D. Morrone, Doctor L. Parreira, Doctor Y. Kim, Doctor J. Lee, Miss F. Vyff...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Baseline demographic and clinical characteristics as predictors of adverse outcomes to improve management of patients with AF receiving edoxaban: a subanalysis of the ETNA-AF registry

About the speaker

Doctor Doralisa Morrone

7 more presentations in this session

Duration of left and right atrial activation wavefront assessed non-invasively is significantly higher in patients with atrial fibrillation than in controls.

The risk and cause of death according to prevalent atrial fibrillation and the role of CHA2DS2-VASc score to stratify the risk of all-cause and cardiovascular death

Lower risk of atrial fibrillation development associated with SGLT-2 inhibitors in type 2 diabetic patients compared to DPP-4 inhibitors: a nationwide cohort study

Impact of atrial fibrillation burden on longitudinal changes in left ventricular structure and function: a post-hoc analysis of a randomized clinical trial

Prognostic significance of thyroid disease in atrial fibrillation

Access the full session

Remodelling, prognosis, and outcomes in atrial fibrillation

About the event

ESC Congress 2023

ESC 365 is supported by